Market open
Kiniksa Pharmaceuticals/$KNSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
315
ISIN
GB00BRXB0C07
Website
KNSA Metrics
BasicAdvanced
$1.8B
-
-$0.24
0.31
-
Price and volume
Market cap
$1.8B
Beta
0.31
52-week high
$28.56
52-week low
$17.38
Average daily volume
674K
Financial strength
Current ratio
3.659
Quick ratio
3.171
Long term debt to equity
1.666
Total debt to equity
2.167
Management effectiveness
Return on assets (TTM)
-1.77%
Return on equity (TTM)
-3.81%
Valuation
Price to revenue (TTM)
3.742
Price to book
3.98
Price to tangible book (TTM)
4.13
Price to free cash flow (TTM)
41.166
Growth
Revenue change (TTM)
59.45%
Earnings per share change (TTM)
-291.46%
3-year revenue growth (CAGR)
89.48%
3-year earnings per share growth (CAGR)
-50.50%
What the Analysts think about KNSA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
KNSA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KNSA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KNSA News
AllArticlesVideos
Kiniksa Pharmaceuticals: Making Steady Progress
Seeking Alpha·1 week ago
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
GlobeNewsWire·2 weeks ago
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $1.8B as of May 15, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 0 as of May 15, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.